Strike three for Rova-T has AbbVie cutting its losses - PMLiVE

Strike three for Rova-T has AbbVie cutting its losses  PMLiVE

AbbVie has run out of patience on its antibody-drug conjugate Rova-T after yet another failed trial in lung cancer, and has decided to abandon the programme.



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Stage 4 Lung Cancer Life Expectancy

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...